Phanes Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Phanes Therapeutics, Inc. - overview
Established
2016
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
Established in 2016 and based in San Diego, US, Phanes Therapeutics, Inc. is biotech company that engages in research and developing innovative drugs in immuno-oncology and eye disease. The company founder and CEO, Dr. Wang Minghan, was a former vice president of Johnson & Johnson.
The company mainly operates two technology platforms, PACbody and ATACCbody. The PACbody platform can constructs native IgG-like bispecific antibodies. The ATACCbody platform can build bispecific antibodies with modulated activities. It aim to use immuno-oncology molecules to treat tumor diseases.
Current Investors
Hong Shan, K2VC, Delos Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.phanesthera.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.